{"task_id": "678f0c8a4801c7b0", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 261/464)", "text": "ess often TST positive\n250\nTuberculosis: Pulmonary\n\n--- Page 272 ---\nCLINICAL FEATURES (CONT\u2019D)\nCOMPLICATIONS OF PULMONARY TB\nhemopty\nsis (rarely massive), pneumothorax (more common in\nendemic countries), bronchiectasis, and pulmonary\ndestruction (rare)\nRelated Topic\nTuberculosis in Pregnancy (p. 412)\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, AST, ALT, ALP, bilir\nubin, albumin, urinalysis\n\u0002\nMICROBIOLOGY\nblood C&S with mycobacterial\nculture, sputum Gram stain/AFB/C&S, urine\nAFB/C&S, HIV serology\n\u0002\nIMAGING\nCXR, CT chest\nSPECIAL\n\u0002\nSKIN TEST\nsee Diagnostic Issues for details\n\u0002\nINTERFERON\nGAMMA\nRELEASE\nASSAYS\nQuanti\nFERON TB Gold In Tube (QFT GIT) assay and\nT SPOT TB assay\n\u0002 PCR\n\u0002\nMOLECULAR FINGERPRINTING\ntracing outbreaks\n\u0002\nSUSCEPTIBILITY TESTING\n1 extra week\n\u0002\nTHORACENTESIS\nif effusion. Send for fluid AFB\nand TB culture\n\u0002\nPLEURAL BIOPSY\n\u0002 CSF\nAFB, TB culture\nDIAGNOSTIC ISSUES\nTUBERCULIN SKIN TEST (TST)\ngold standard for\ndiagnosing latent tuberculosis (epidemiologic tool),\nbut not sensitive or specific to include or exclude\nactive pulmonary TB. Given as 5 units TST S (purified\nprotein derivative) intradermally, measure extent of\ninduration after 48 72 h. Skin test reaction cutoffs\nand corresponding population groups when test con\nsidered positive (in North America) are as follows:\n\u0002 \u00035 MM\nHIV positive, recent TB contact, CXR\nsigns, prior TB\n\u0002 \u000310 MM\nother risk factors for infection (ende\nmic, immigrant, aboriginal, homeless, injection\ndrug user, healthcare worker, silicosis, kidney or\nliver disease, gastrectomy, ileal bypass)\n\u0002 \u000315 MM\nno risk factors\nSPUTUM SMEAR\n\u0002\nUTILITY\nmorning sputum \u00053 days (AFB, TB cul\nture), induced sputum if necessary, bronchoscopic\nlavage if cannot obtain sputum. Three consecutive\nDIAGNOSTIC ISSUES (CONT\u2019D)\nAFB negative\nsputum\nsamples\nsupport\nthat\npatient is non infectious and can come off isolation\n\u0002\nLIMITATIONS\nsmear only detects 50% of culture\npositive TB, and in non endemic areas positive\nsmear may represent non TB mycobacterium\n\u0002\nSTAINING AGENTS\nstandard is Ziehl Neelsen (acid\nfast stain); Auramine Rhodamine or Auramine O\nfluorescence staining improves sensitivity but\nmust be confirmed with acid fast\nSPUTUM CULTURE\n2 8 weeks in egg media, 4 14\ndays if radiometric (sens 80 85%, spc 98 99%)\nPOLYMERASE CHAIN REACTION (PCR)\nmore use\nful in non endemic countries to rule out other com\nmon mycobacteria. High specificity but variable sen\nsitivity (if AFB positive, sens 94 96%, spc 99.7 100%.\nIf AFB positive, sens 9 100%, spc 25 100%)\nINTERFERON GAMMA RELEASE ASSAYS\nsensitiv\nity >95%; not affected by prior BCG vaccination. Most\nuseful for evaluation of latent TB in those with posi\ntive TST and previously vaccinated with BCG\nMANAGEMENT\nLATENT TB INFECTION\nisoniazid 300 mg PO daily\n\u00056 12 months or rifampin 600 mg PO daily \u00054\nmonths. A \"decision to tuberculin test is a decision\nto treat\u2019\u2019 with no age cutoff for treatment and regard\nless of BCG vaccination status. Exclude active TB with\nsputum culture and CXR before treatment. HIV,\nimmunosuppressed, and newly infected patients\nshould be priority for treatment of latent TB\nPRIMARY OR REACTIVATION TB\npatients should\nbe isolated in single rooms with negative air pressure.\nTB therapy should be undertaken in consultation with\nan expert. Susceptibility testing is necessary to guide\ntreatment. Directly observed treatment (DOT) is the\nstandard of care for all patients. TB therapy consists of\nan intensive phase of daily therapy followed by a\ncontinuation phase of twice or thrice weekly therapy.\nwRIPEw Rifampin 10 mg/kg or 600 mg PO daily,\nisoniazid 5 mg/kg or 300 mg PO daily, pyrazinamide\n20 25 mg/kg PO daily \u00058 weeks. Ethambutol\n15 20 mg/kg PO daily is added until drug suscept\nibility results are available. This is followed by isonia\nzid and rifampin daily, twice weekly, or three times\nweekly for 16 more weeks. Alternatives include iso\nniazid, rifampin, pyrazinamide, plus ethambutol or\nstreptomycin three times weekly for 24 weeks, or\nisoniazid, rifampin, pyrazinamide, plus ethambutol\nfor 2 weeks, then twice weekly for 6 weeks, followed\nby isoniazid and rifampin twice weekly for 16 weeks\n(see guidelines for exceptions and alternate regimens\nwhen faced with resistance or drug intolerance)\nTuberculosis: Pulmonary\n251", "text_length": 4257, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 261/464)", "type": "chunk", "chunk_index": 260, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.606462", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.607163", "status": "complete", "chunks_added": 3}